SPEAKER BIOGRAPHIES: Higher Throughput Protein Purification
Joshua LaBaer, M.D., Ph.D., Virginia G. Piper Chair in Personalized Medicine, Director, The Biodesign Institute; Personalized Diagnostics, Arizona State University
Joshua LaBaer, M.D., Ph.D., formerly the Director of the Harvard Institute of Proteomics (HIP), is the Piper Chair in Personalized Medicine, Director of the Virginia G. Piper Center for Personalized Diagnostics and the Chair of the Directorate of the Biodesign Institute. His efforts involve leveraging the Center's formidable resources for the discovery and validation of biomarkers—unique molecular fingerprints of disease—which can provide early warning for those at risk of major illnesses, including cancer and diabetes. He completed medical and graduate school at the University of California, San Francisco where he studied steroid regulation of DNA transcription and protein-DNA interactions. He completed his internship and residency at the Brigham and Women's Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute in Boston. Dr. LaBaer is a member of the National Cancer Institute Board of Scientific Advisors. Recently he was elected Chair of the EDRN Executive Committee and Co-Chair of the Steering Committee. Dr. LaBaer serves as an associate editor of the Journal of Proteome Research, and a member of the editorial boards of Analytical Chemistry, Current Opinion in Biotechnology, Cancer Biomarker, Molecular Biosystems, and Clinical Proteomics. He is treasurer and president-elect for US Human Proteome Organization (USHUPO) and a member of the Scientific Advisory Committee for Plexera.
Guy Poirier, Ph.D., Canada Chair, Targeted Proteomics, Laval University and Chuq Research Center, Quebec
Dr. Guy G. Poirier holds a Tier 1 Canada Research Chair in targeted proteomics and is full professor at the Faculty of Medicine, University Laval, Quebec, Canada. Professor Poirier is interested in two main research fields: apoptosis and proteomics. He is a leader in the field of proteomics of poly(ADP-ribose) binding protein and a specialist in the study of DNA damage sensing enzymes (PARP) that play a fundamental role in signaling DNA damage and in its repair. A better understanding of DNA damage signals and of a phenomenon known as apoptosis (programmed cell death) will greatly improve the diagnosis and treatment of widespread diseases such as cardiovascular disease, diabetes, neurodegenerative diseases and several types of cancer. As a matter of fact, PARP inhibitors are used successfully in cancer therapy. His work on poly(ADP-ribose) has led to major discoveries on the role of PARPs in apoptosis (involvement and discovery of caspases), DNA repair and stability of genome integrity (Lazebnik et al 1994 Nature, cited 1200 times; Rouleau et al, Nature Cancer Reviews, 2012). In 2006, in collaboration with the Dawson's group at Johns Hopkins University, he developed for the first time a PARG-deficient mouse. This genomic disruption delays the nervous systems development and is lethal at the embryonic stage. The two groups also studied the critical role of AIF in cell death in the nervous system and of E3 ligase RNF146 (published in Nature and Science). Concurrently, Dr Poirier has developed a proteomics platform. At the international level, in 2010, Dr Poirier was the founding president of CNPN (Canadian National Proteomic Network) which organizes key meetings at national and international levels (HUPO, Human Proteome Organization).
Douglas MacDonald, M.S., Senior Process Development Engineer II, Purification Process Development, Dendreon Corp.
Doug MacDonald graduated with a M.S. in Chemical Engineering from the University of Washington in 2000. He began his career at Immunex where he contributed to the successful implementation and scale-up of a post-capture refolding step of an Fc:fusion protein. After Immunex was acquired by Amgen, he continued work on the purification process development of four mAbs. Doug is very interested in new technology development, including custom resins and charged filters and had dedicated a significant amount of time to the area of high throughput screening (HTS) in downstream process development. Upon joining Dendreon in 2009, he brought the HTS technology to the forefront and has led the efforts in making this technology a practical alternative to initial downstream process development. He currently leads process development projects using 96-well filter plates and RoboColumns, and has used this technology to troubleshoot commercial processes.
W. Clay Brown, Ph.D., Scientific Director, High-Throughput Protein Lab, Center for Structural Biology, Life Sciences Institute, University of Michigan
I earned my Ph.D. at Wayne State University in Detroit and did a post-doc at the California Institute of Technology before beginning my career at Amgen in the Bacterial Expression department. At Amgen I worked on the development of proprietary systems for the production of biotherapeutic targets in bacteria. I then established an insect cell production lab supporting structural biology and high-throughput screening efforts. I later moved to Pfizer to become the head of Expression Technologies at the Ann Arbor site. At Pfizer I directed three separate groups producing reagents in bacterial, insect, and mammalian systems responsible for all in-house protein and cellular reagent provision for this site. I was also responsible for overseeing development of formats suitable for automation and headed a team identifying and implementing automation and technologies for optimizing bioprocesses. Now at the University of Michigan, I am Scientific Director of the High-Throughput Protein laboratory in the Center for Structural Biology. The mission of this lab is to provide services and support to life sciences researchers across the campus for the identification of constructs and conditions that lead to high yields of soluble protein expression in bacteria, insect cells and we are just launching a mammalian service. I also pursue basic research into developing molecular biology tools such as ligation-independent cloning vectors compatible with each system, alternative promoters and solubilizing fusion partners.
Nien-Hwa Linda Wang, Ph.D., Professor, Chemical Engineering, Purdue University
Dr. Nien-Hwa Linda Wang is a Professor of Chemical Engineering at Purdue University. She has been teaching and doing research at Purdue since 1980. She obtained her BS in Chemical Engineering from National Taiwan University in 1971, MS in Chemical Engineering from the University of Wyoming in 1973, and PhD in Chemical Engineering from the University of Minnesota in 1978. She is a Fellow of the American Institute of Medical and Biological Engineering and the American Institute of Chemical Engineers. She was a Director of the Separations Division, American Institute of Chemical Engineers (2001-2004) and a Director of the International Adsorption Society (2001-2007). She is currently the vice chair of the Separations Division, AIChE (2012). She has also served as a consultant to NIH, NSF, four national laboratories, and 15 chemical, food, and pharmaceutical companies.
She is internationally known for her research contributions in adsorption, ion exchange, multi-component chromatography, and simulated moving bed technologies. She has more than 100 technical publications, two patents, and more than 200 invited lectures and presentations at national and international meetings. She has developed several important chromatography and simulated moving bed technologies that are applicable to the design of a wide range of adsorption and ion exchange separations. These technologies include VERSE (a comprehensive simulation package for chromatography based on a detailed rate model), the Standing Wave Design method for simulated moving beds, and new Versatile Simulated Moving Bed Equipment. Her current research is focused on the separations of chiral molecules, lanthanides, proteins, and polymers.
Dietlind L. Gerloff, Ph.D., Assistant Professor, Biomolecular Engineering, School of Engineering, University of California, Santa Cruz
Dr sc nat, Department of Chemistry, ETH Zurich 1994
Swiss National Science Foundation and Leukemia Society of America Postdoctoral Fellow,
Department of Cellular & Molecular Pharmacology, University of California San Francisco 1995-1998
Lecturer in Bioinformatics, University of Edinburgh 1999-2006
Joined UC Santa Cruz in 2006.
Eric M. Nicholson, Ph.D., Lead Scientist, Prion Diseases Research Project, National Animal Disease Center, USDA, Agriculture Research Service
Dr. Nicholson is a Research Chemist and the Lead Scientist of the Prion Diseases Research Project at the USDA, Agriculture Research Service, National Animal Disease Center. His lab applies biochemical and biophysical approaches to address various aspects of the pathobiology of prion diseases found in livestock species. Prior to joining the USDA, Dr. Nicholson studied the folding and misfolding pathway of the prion protein as a Damon Runyon postdoctoral fellow at the University of California, Berkeley. Dr. Nicholson earned his Ph.D. from the Biochemistry and Biophysics Department at Texas A&M University in 1993 where he conducted research on the thermodynamics of protein conformational stability in the lab of Dr. J. Martin Scholtz. Dr. Nicholson earned a B.S. degree in Biochemistry from Kansas State University in 1993.
William Gillette, Ph.D., Senior Scientist, Protein Expression Lab, SAIC-Frederick, Inc.
Bill Gillette is currently focusing on high-throughput micro-scale purification as a means to identify positive constructs, optimization of chromatography and supporting analysis techniques to evaluate protein expression constructs and the success of the micro scale chromatography experiments. His work is in the context of the Protein Expression Laboratory that provides protein expression/purification core service to the laboratories of the NCI, NIH and USAMRIID. He received his Ph.D. in Microbiology from NC State University, Raleigh, NC.
Renaud Vincentelli, Ph.D., Engineer & Head, Method Development, Architecture et Fonction des Macromolécules Biologiques (AFMB), CNRS/Marseille University
Renaud Vincentelli, coordinator of the structural genomics facility of AFMB, joined the lab in 2001 to set-up one of the first highthroughput (HTP) protein production facilities in Europe. Prior to joining the AFMB, Renaud spent 9 years producing proteins at EMBL. At AFMB, hebuilt up and implemented an HTP protein expression platform in E.colithat was involved in several European-wide collaborative projects. The development of methods is constant and, in the last few years, new HTP protocols for in-vitro protein-protein and protein-DNA interactions studies have been implemented and validated on hundreds of proteins at the facility. Renaud co-organized the first as well as the last European EMBO course on HTP methods in Marseilles (2005 and 2011) and has been teaching HTP protein expression protocols at several EMBO courses over the years.
Susanne Gräslund, Ph.D., Principal Investigator, Biotechnology, Structural Genomics Consortium, University of Toronto
Susanne Gräslund did her doctoral training in Biotechnology at the Royal Institute of Technology in Stockholm, Sweden. After her dissertation in 2002 she worked for three years at Biovitrum AB in the Target Expression & Purification section. In March 2005, Susanne joined the newly started Structural Genomics Consortium group in Stockholm, heading the Biotechnology team responsible for the generic protein production pipeline. She was then recruited to the SGC Toronto site as Principal Investigator for the Biotechnology team in September 2011.
Richard Wu, Ph.D., Senior Scientist, Process & Product Development (P&PD), Amgen, Inc.
Richard Wu obtained his Ph.D. degree in Analytical Chemistry from the University of Washington at Seattle in 2003 where he was also a fellow researcher in the Center of Process Analytical Chemistry (CPAC) organization. He is currently a senior scientist in the process and product development (P&PD) department at Amgen Thousand Oaks, California, USA. He leads the analytical core services (ACS) group in ATO where the group provides assay support to internal clients. His group extensively utilizes automatic and high-throughput instrumentation and methodology with the aims of quicker analytical result turnaround, improved analytical data quality, and efficient use of company's resources.
Michael R. Buchmeiser, Ph.D., Professor and Vice Dean, Institute of Polymer Chemistry, University of Stuttgart
Michael R. Buchmeiser was born in Linz, Austria. He received his Ph. D. in Organometallic Chemistry in 1993 from the University of Innsbruck, Austria He was awarded an "Erwin Schrödinger Fellowship" and spent one year at the MIT within the group of Prof. Richard R. Schrock (Chemistry Nobel Prize 2005). In 1998, he finished his "Habilitation" in Macromolecular Chemistry (University of Innsbruck) were he then held a Faculty Position as Associate Professor from 1998-2004. He received the "Professor Ernst Brandl Research Award 1998", the "START Award-2001" the "Novartis Award 2001" as well as the "Otto-Roelen Medal of the Gesellschaft Deutscher Katalytiker" der GDCh. He was offered Faculty Positions (Full Professor of Polymer Chemistry) at the University of Halle (Germany) in 2004, at the University of Leoben (Austria) in 2005 and at the TU Dresden in 2007, which he all declined. Instead, since December 2004, he accepted a Faculty Position (C-4 Professor) at the University of Leipzig, Germany. In addition, from 2005-2009, he served as Vice Director and Member of Board at the Leibniz Institute of Surface Modification (IOM), Leipzig, Germany. In December 2009, he took over a Faculty Position (Full Professor) at the University of Stuttgart (Germany) as well as the position of the Director of the Institute of Textile Chemistry and Chemical Fibers. So far, he has published more than 250 research papers and has filed approx. 20 patents.
Garwin Pichler, Ph.D., Scientist, Ludwig Maximilians University, Munich
Garwin Pichler obtained his Ph.D degree in Biology from the Ludwig-Maximilians-University in Munich in 2012 where he was working on the crosstalk between DNA methylation and histone modifications. During his Ph.D, he developed new technologies to study biochemical and functional characteristics of fluorescent fusion proteins, revealing that the multi-domain proteins Uhrf1 and Uhrf2 cooperatively connect the two major repressive epigenetic pathways. He is currently a postdoctoral fellow at the Ludwig-Maximilians-University in Munich working on the cell cycle-dependent regulation of Dnmt1 by interactions and modifications.
Yiming Yang, Senior Scientist, Purification Process Development, Shire Human Genetic Therapies
Yiming Yang is a senior scientist in purification process development at Shire HGT. He has eighteen years of support experience in protein purification, process development, process optimization, scale-up, tech transfer, and manufacturing. He was a group leader in designing and developing purification processes for two FDA approved therapeutic proteins. Currently, he is working on a late stage program.